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Abstract
Background—A history of diabetes is associated with an increased risk of several types of
cancers. Whether diabetes is a risk factor for head and neck cancer (HNC) has received little
attention.
Methods—We pooled data from 12 case-control studies including 6,448 cases and 13,747
controls, and estimated odds ratios (OR) and 95% confidence intervals (CI) for the associations
between diabetes and HNC, adjusted for age, education level, sex, race/ethnicity, study center,
cigarette smoking, alcohol use and body mass index (BMI).
Results—We observed a weak association between diabetes and the incidence of HNC overall
(OR, 1.09; 95% CI, 0.95–1.24). However, we observed a modest association among never
smokers (OR, 1.59; 95% CI, 1.22–2.07), and no association among ever smokers (OR, 0.96; 95%
CI, 0.83–1.11); likelihood ratio test for interaction p=0.001.
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Conclusions—A history of diabetes was weakly associated with HNC overall, but we observed
evidence of effect modification by smoking status, with a positive association among those who
never smoked cigarettes.
Impact—This study suggests that glucose metabolism abnormalities may be a HNC risk factor in
subgroups of the population. Prospective studies incorporating biomarkers are needed to improve
our understanding of the relationship between diabetes and HNC risk, possibly providing new
strategies in the prevention of HNC.
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Introduction
Diabetes and/or abnormal glucose metabolism are associated with an increased risk of
various types of cancers, including colorectal (1), pancreatic (2), breast (3), liver (4) and
endometrial cancer (5). There are several mechanisms through which diabetes may drive the
carcinogenic process. Neoplasms have an inherently high need for glucose to fuel
proliferation, raising the possibility that untreated hyperglycemia may contribute to tumor
growth (6). Diabetics also exhibit increased generation of reactive oxygen species and
greater oxidative damage to DNA (7,8). Exposure to high levels of insulin and insulin-like
growth factors (IGFs), a hallmark of type II diabetes, results in increased cellular
proliferation. The IGF receptor additionally activates the oncogenic epidermal growth factor
receptor (EGFR) (9). In addition, IGFs also appear to exert anti-apoptotic effects (10–12).
Head and neck cancers (HNC) are among the most common worldwide, with an estimated
nearly 400,000 new cases and approximately 200,000 deaths in 2008 worldwide (13). While
tobacco, alcohol use and, infection with oncogenic HPV are established risk factors for HNC
(14,15), emerging evidence suggests that abnormalities of glucose metabolism and diabetes
may also play a role (16–19). Several studies have reported that diabetics have an increased
prevalence of oral lesions such as erythroplakia and leukoplakia that predispose to oral
cancer (17–19). A Danish population-based study comparing individuals hospitalized with a
diagnosis of diabetes to the general population observed an increased risk of mouth/pharynx
cancer associated with diabetes in subjects less than 50 years old but not in older persons
(20); however, these results were based on only 30 cases. A hospital-based case-control
study of 2,660 patients and 2,980 controls observed that elevated fasting glucose was
strongly associated with oral cancer in females but not males (16).
We used pooled data from multiple studies from different countries to investigate whether a
history of diabetes is associated with HNC overall, as well as within subgroups defined by
known HNC risk factors.
Methods
Overview and Design
We conducted a pooled analysis of case-control studies participating in the International
Head and Neck Cancer Epidemiology (INHANCE) Consortium. Data pooling methods for
the INHANCE consortium have been previously described (21). The following 12
INHANCE studies collected data on diabetic status: Milan (22), Aviano (23), Italy
Multicenter (24), Switzerland-Vaud (25), Germany-Saarland (26), Seattle (OralGen) (27),
Seattle (LEO) (28), Tampa (29), Los Angeles (30), Rome (31), Japan (32), and North
Carolina (33). The 12 studies comprised 6,448 cases and 13,747 controls for which data on
diabetic status, as well as on HNC risk factors and other characteristics were available.
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Cases were patients with tumors classified by the original studies as invasive tumors of the
(1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, (5) oral cavity or pharynx not
otherwise specified or (6) HNC unspecified, as defined previously (21). The pooled studies
were all hospital-based, except for both Seattle studies, the North Carolina study and the Los
Angeles study. For these four studies, cases were identified from population-based cancer
registries. For all of the included studies, controls were frequency-matched on age and sex,
with the exception of the Los Angeles study, for which controls were individually matched
on age, sex and neighborhood. The Italy Multicenter study additionally matched on center,
and the Tampa and North Carolina study additionally matched on race/ethnicity. The date of
reference was defined as the date of diagnosis for cases and the date of selection for
controls, except for the Seattle (OralGen) study (27)where the reference date for a particular
control subject was assigned at random from among the possible case subject diagnosis
dates (27). The North Carolina, Tampa and Rome studies restricted eligibility to case
subjects with squamous cell carcinomas (SCC). For the other studies, SCC was identified by
ICD-O-2 or ICD-0-1 histologic codes, with the exception of the Milan, Aviano and Italy
Multicenter study, for which no data were available on histologic type. We excluded all
known non-SCC cases (n=205).
Measures and Data Collection
Data collection procedures regarding the data pooling and harmonization have been
described in detail (21). All interviews for the studies used in this pooled analysis were face-
to-face interviews, with the exception of the Germany-Saarland study, for which a self-
administered questionnaire was used. Blank questionnaires were collected from the studies
to assess comparability and wording of interview questions. Data from each study were
received at the INHANCE Data Coordination Center with personal identifiers removed.
Each data item was checked for illogical or missing values and queries were sent to the
investigators to resolve inconsistencies.
We classified diabetic status as a binary variable (yes/no). Studies from Tampa, Los
Angeles, Rome, North Carolina, Seattle (OralGen) (27), Seattle (LEO) (28), Germany, and
Japan had a specific question in the interview that asked whether the subject had ever been
diagnosed with diabetes (yes/no). The interview from the Milan, Aviano, Italy, and
Switzerland-Vaud studies asked for the age at diabetes, coded as zero for no history of
diabetes. Nine out of 12 studies had data on age or date at diagnosis, and this variable was
used to estimate duration of diabetes (continuous). Only the Rome study collected
information on whether subjects with a history of diabetes were diagnosed with type I or
type II diabetes, or had used insulin or oral hypoglycemic agents.
Other relevant subject characteristics, including ethnicity, education, tumor site and
histology, cigarette smoking, other tobacco habits, alcohol consumption, height, and weight
were harmonized across studies, as described previously (21). Pack-years of cigarette
smoking was calculated by multiplying packs (defined as 20 cigarettes) of cigarettes per day
and number of years smoking. Alcohol consumption was standardized across studies by first
converting beverage-specific number of drinks to ethanol volume in milliliters. The average
daily number of ethanol-standardized drinks was then calculated as frequency of
consumption of each alcoholic beverage type weighted by the corresponding duration, with
the exception of the Tampa, Rome and Germany-Saarland studies in which the average of
the frequency of all alcoholic beverage type was used (due to missing data for duration)
(34).
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Body mass index (BMI) was calculated as weight (in kilograms) divided by height squared
(in square meters). Height and weight at the reference date were self-reported. One study
also collected data on height and weight 2–5 years prior to diagnosis, and three studies
collected data on height and weight between ages 20–30 years. In a previous INHANCE
study on the relationship between BMI and HNC, results were similar for analyses using
BMI at these differing time periods (35). We thus used BMI at reference date in the analyses
for simplicity and completeness.
A number of subjects were missing data on education level (13% of cases and 26% of
controls) and BMI (10% of cases and 5% of controls). There were also a small amount of
missing data for smoking (1.8% of cases and 1.6% of controls) and alcohol use (3.5% of
cases and 2.0% of controls). We thus imputed data on these characteristics conditional upon
covariates by using a ‘MICE’ procedure (multiple imputation by chained equations),
developed for use in STATA as ‘ICE’ (36). This algorithm uses a sequence of regression
equations to impute missing data conditional on other predictors, cycling through the
equations until all variables have complete data. We used age, sex, race/ethnicity, study,
case/control status, education level, BMI, smoking status, pack years of smoking, alcohol
drinking status, and alcohol drinks per day (excluding the variable to be imputed) to impute
the missing data.
Statistical Analyses
We estimated adjusted odds ratios (OR) and 95% CI using unconditional logistic regression
models. We performed three levels of covariate adjustment: (1) a minimally adjusted model
that controlled for age (categorical), sex, education level (categorical), race/ethnicity
(categorical), and study center; (2) a model that adjusted for age, sex, education level, race/
ethnicity, study center, pack-years of cigarette smoking (continuous), and alcohol drinks per
day (continuous); and (3) a model controlling for all the previously listed covariates as well
as BMI (continuous). We did not adjust for pipe or cigar smoking because of a substantial
amount of missing data for these covariates. Based on previous research that suggested an
association between diabetic status and oral cancer risk among women, but not among men
(16), we calculated adjusted odds ratios for men and women separately in all primary
analyses.
To determine whether a history of diabetes is a risk factor for HNC for those cases not
associated with excess tobacco/alcohol, we stratified by cigarette smoking and alcohol
drinking status. To statistically assess departures from multiplicative effects on the odds
scale we included product terms in these stratified analyses, and used a log-likelihood ratio
test to compare logistic models with and without the product terms.
To attempt to disentangle the effects of obesity and diabetes on HNC risk and to explore
possible interactions, we also stratified by BMI using categories recommended by the World
Health Organization (obese ≥ 30; overweight ≥ 25 and < 30; normal, ≥ 18.5 and < 25; and
underweight, < 18.5). The previous INHANCE study on the relationship between BMI and
HNC reported effect modification by tobacco alone and by tobacco/alcohol (35). We
therefore stratified by BMI in analyses that additionally dichotomized subjects according to
tobacco use (ever/never).
To determine whether duration of diabetes is associated with HNC risk, we estimated
adjusted ORs for the following exposure categories: (1) no history of diabetes; (2) duration
of diabetes less than 10 years; and (3) duration of diabetes greater than 10 years. Based on a
previous study showing differential results according to age at diabetes diagnosis (20), we
estimated adjusted ORs for the categories: (1) no history of diabetes; (2) diabetes diagnosis
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before age 50; and (3) diabetes diagnosis after age 50. We additionally examined diabetes
diagnosis before or after age 50 stratified by duration of diabetes.
To address possible selection bias due to control participants being systematically healthier
than non-participants, we repeated the main analyses after dichotomizing the pooled studies
according to participation proportions (<90% (five studies) vs, *≥90% (five studies)). These
participation rate percentages were available for all studies, with the exception of the
Germany-Saarland study.
We categorized cases by tumor site and performed polytomous logistic regression to assess
how the association with diabetes varied across tumor sites. We derived study-specific and
summary estimates and evaluated the extent of between-study heterogeneity using the Stata
“Metan” command for random effects meta-analyses (37). Finally, we used the “Metainf”
module (38) for “leave-one-out” influence analyses to determine whether the associations
were dependent on any one study. We used Stata statistical software (version 10.0, Stata
Corp.) for all analyses.
Results
Cases were more likely to be male, non-Hispanic White, cigarette smokers, alcohol drinkers,
and to have lower BMI compared to controls (Table 1). Of the cases, 18.9% had cancer of
the oral cavity, 26.3% had oropharyngeal cancer, and 33.1% had cancer of the larynx. The
majority of cases (64.4%) were known to be squamous cell carcinomas, with a sizeable
proportion of cases having unknown histologic type (32.5%).
Diabetes was not associated with HNC overall in models adjusted for age, race, sex, study
center, education level, pack-years of cigarette smoking, and alcohol drinks per day (OR,
0.95; 95% CI, 0.83–1.08; Table 2) and was weakly associated in models that additionally
adjusted for BMI (OR, 1.09; 95% CI, 0.95–1.24). Results for minimally adjusted models
were similar to results obtained with adjustment for age, race, sex, study center, education
level, pack-years of cigarette smoking, and alcohol drinks per day. ORs were slightly higher
for women than for men (Table 2), but a comparison of models with and without a product
term for sex and diabetes yielded p=0.09. Adjustment for BMI reported at age 20 to 30,
versus BMI reported at the reference date, did not materially affect the estimates (results not
shown).
The adjusted association between diabetes and HNC was stronger among never smokers
(fully adjusted OR, 1.59; 95% CI, 1.22–2.07) than among ever smokers (fully adjusted OR,
0.96; 95% CI, 0.83–1.11; p=0.001 for homogeneity of the OR; Table 3). The pattern of
results among never smokers and never alcohol drinkers versus ever smokers and drinkers
was similar to those obtained by stratification on smoking status alone, but ORs were not as
high in the never smoking-drinking category as those obtained in the never smoking
category. There was an interaction by smoking status in comparisons of models that did and
did not include a product interaction term for smoking and diabetes (likelihood ratio
p=0.001), but not in models with and without an interaction term for alcohol and diabetes
(p=0.36). In analyses that classified smoking status as never, former or current, the OR’s
were highest for never smokers (fully adjusted OR, 1.61; 95% CI, 1.24–2.10; Supplemental
Table 1), lower for former smokers (fully adjusted OR, 1.14; 95% CI, 0.94–1.39) and lowest
for current smokers (fully adjusted OR, 0.91; 95% CI, 0.73–1.12).
We observed little departure from multiplicativity of effects for diabetes and BMI
(likelihood ratio p=0.25), and there was no discernable pattern in the results of analyses
stratified by BMI, either overall or dichotomized by sex (results not shown). Among never
smokers, there was a slight indication of an elevated risk of HNC associated with diabetes
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among normal weight and overweight subjects (fully adjusted OR, 1.64; 95% CI, 0.92–2.93
and fully adjusted OR, 1.42, 95% CI, 0.86–2.33 respectively), but not underweight or obese
subjects (fully adjusted OR, 1.13; 95% CI, 0.37–3.49 and fully adjusted OR, 1.12, 95% CI,
0.66–1.92 respectively).
There was no strong evidence of heterogeneity by tumor site in the association between
diabetes and HNC (Supplemental Table 2). In sex-specific strata, results for women were
close to unity for all sites except the hypopharynx; however, wide confidence intervals limit
interpretation. There was some indication of heterogeneity by tumor site when analyses were
stratified by smoking status (Supplemental Table 3). Among never smokers, ORs appeared
to be greatest for oral cavity and larynx cancers, with null results for oropharyngeal cancers.
However, small sample sizes within strata limited our ability to draw meaningful
conclusions. In a fully-adjusted polytomous logistic regression model, we did not observe
associations between history of diabetes and HNC risk across tumor sites.
Compared to subjects with no history of diabetes, those with diabetes for less than 10 years
had a small elevated OR (fully adjusted OR, 1.15; 95% CI, 0.95–1.39; Supplemental Table
4), with similar results obtained for those with diabetes greater than 10 years (fully adjusted
OR, 1.16; 95% CI, 0.90–1.49). Compared to non-diabetics, we observed an elevated
association between HNC and diabetes diagnosed before age 50 (fully adjusted OR, 1.37;
95% CI, 1.07–1.74), and no association for those diagnosed after age 50 (fully adjusted OR,
1.00; 95% CI, 0.83–1.20). We observed the same pattern for men, but ORs for women
diagnosed before and after age 50 were both similarly elevated. An analysis of diabetes
diagnosis before or after age 50 stratified by duration of diabetes did not provide meaningful
results due to small stratum specific numbers, and did not yield evidence of a particularly
unique subgroup (results not shown).
Among the eleven studies with information on control participation proportions, the fully
adjusted OR was 1.09 (95% CI, 0.96–1.24). The estimate from five studies with control
participation rates below 90% (OR=1.11; 95% CI, 0.89–1.38) was similar to the estimate
from six studies with control participation rates above 90% (OR=1.09; 95% CI, 0.92–1.29).
There was evidence of heterogeneity in a meta-analyses of the study-specific ORs (chi-
squared p=0.002; Figure 1). “Leave-one-out” influence analyses indicated that the North
Carolina study had a large impact on results, due to its unique inverse relationship between
diabetes and HNC (Figure 2). The association between history of diabetes and HNC in fully
adjusted models was greater when the North Carolina study was excluded (OR=1.19; 95%
CI, 1.02–1.38). Similarly, the association among never smokers was appreciably increased
after exclusion of the North Carolina study (OR=1.91; 95% CI, 1.39–2.62); with the
association among ever smokers increasing slightly after exclusion, but remaining close to
unity (OR=1.07; 95% CI, 0.90–1.26).
Discussion
In this large pooled analysis of 12 international studies, we observed a weak association
between history of diabetes and risk of HNC overall. However, we observed a stronger
association between history of diabetes and HNC in never smokers. In addition, we observed
a positive association between diabetes diagnosed before age 50 and HNC.
An association between history of diabetes and HNC only in never smokers may exist if the
diabetic condition affects an, as yet, unknown causal pathway for HNC among never
smokers. Alternatively, a substantial proportion of people who are both heavy smokers and
diabetic and who would have developed HNC in the future, may be at particular risk for
early death or illness, and may have died before developing HNC. A third possibility is that
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adjustment for pack years of smoking is not sufficient to remove all confounding among
smokers, and that examining the association between a history of diabetes and HNC among
never smokers circumvents this source of residual confounding. This possibility is supported
by results from studies on the association between HNC and BMI, which is strongly
associated with diabetes (39,40). A recent INHANCE pooled analysis observed an
etiologically improbable reduced risk of HNC associated with overweight and obesity even
after adjustment for duration and intensity of smoking (35). However, when analyses were
confined to never smokers, the reduced risk associated with overweight and obesity was
attenuated to the null.
We observed a positive association between HNC and diabetes diagnosed before age 50, and
no association for those diagnosed after age 50. Only 5 cases and 9 controls were diagnosed
with diabetes before age 20, making it unlikely that these results were due to the inclusion of
type I diabetics. Cases diagnosed as diabetic before age 50 had a mean age of 55 at HNC
diagnosis and a mean duration of diabetes of 15 years, while cases with a diabetes diagnosis
over age 50 had a mean age of 64 at HNC diagnosis and a mean diabetes duration of 6 years.
These data suggest that a younger age of type II diabetes onset may confer particular risk for
subsequent development of HNC, and that these cancers may develop at a relatively young
age. The difference according to age may partly be explained by the observation that
younger HNC patients are less likely to have extensive histories of tobacco and alcohol use
(41,42). The longer duration of exposure to the diabetic condition could also explain the
increased risk for younger patients. In addition, it has been suggested that adults diagnosed
with diabetes at a younger age may represent a more aggressive phenotype than people
diagnosed late in life (43), and thus the diabetic condition in older people may not
predispose to HNC to the same degree as in younger diabetics. The exclusion of several
studies due to lack of diabetes diagnosis age data and the small numbers in each of the strata
limit interpretation of these results.
Results from the majority of studies in these pooled analyses indicated a positive
relationship between history of diabetes and HNC, with the notable exception of the North
Carolina study, for which an inverse relationship was observed. Subjects from the North
Carolina study made up 14% of the total pooled sample, resulting in a relatively heavy
influence of this study on the overall results. A notable difference in the North Carolina
study is the high prevalence of diabetes among controls (17%) (44) compared with controls
from other US studies and other countries (mean prevalence of 6% in controls for all other
studies). The North Carolina study population had a larger proportion of African Americans
than other studies; however race is unlikely to play a role because cases and controls were
frequency matched on race and estimates were adjusted for race.
Our results support previous research suggesting involvement of abnormal glucose
metabolism in HNC. Suba et al. conducted a hospital-based case-control study in Hungary in
2,660 in-patients with confirmed OSCC and 2,980 “complaint-free” controls who
volunteered to participate in oral cancer screenings during the same period, and observed
that repeatedly elevated (>5.5 mmol/l) fasting glucose over a period of 4 days was strongly
associated with oral cancer in females (OR, 1.61; no 95% CI reported; p<0.05), but that no
such association existed in males (OR, 0.97; p>0.05) (16). Cases and controls were matched
on age, but no adjustment was made for, or effect modification examined with, known
OSCC risk factors. In a study on the risk of multiple cancers in a nationwide cohort of
diabetics in Denmark, Wideroff et al. reported increased risk of mouth/pharynx cancer
associated with diabetes (20). However, there were only 30 cases in those analyses.
Additionally, the association was only observed in subjects less than 50 years old at diabetes
diagnosis (standardized incidence ratios (SIR) based on age, sex and calendar year, 1.8; 95%
CI, 1.2–2.6). The estimates were similar for males and females.
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In a previous pooled INHANCE study, it was observed that HNC risk is elevated among
lean people and reduced among overweight or obese people (35). If overweight and obesity
are negatively associated with HNC, it could be argued that this makes a positive association
between diabetes and HNC less likely since obesity is strongly associated with conditions
such as metabolic syndrome, and an increased risk of developing insulin resistance,
followed by glucose intolerance and type II diabetes (45,46). However, glucose intolerance
can also occur independently of insulin resistance (46–48).
Diabetes is emerging as more of a heterogeneous disease than initially thought, with
subtypes of people who are classified as type II diabetics, but who exhibit defects in insulin
secretion with no evidence of insulin resistance. Examples include maturity-onset diabetes
of the young (MODY) (49) and mitochondrial diabetes (50). There are also populations that
have type II diabetes, especially in Asia, who are not overweight or obese by Western
criteria. For example, in a study of type II diabetics in Taiwan, only 43% of women and
48% of men had a BMI greater than 25 kg/m2 (51). These observations suggest that,
although there is an association of overweight with diabetes, the diabetic condition is a
distinct disease state that frequently also develops in people who are not overweight.
Hyperglycemia and associated biochemical consequences, independent of obesity-linked
characteristics of diabetes, may be a mechanism by which diabetes increases the risk of
cancer. Interestingly, several prospective cohort studies indicate that cancer risk starts to
increase at blood glucose levels even below the diabetic range. Studies in Korea (52),
Austria (53) and Sweden (54)found a linear increase in risk for multiple cancers across the
entire spectrum of glucose values, regardless of weight.
A limitation of this study is that we were only able to examine self-reported diabetic status,
which may have resulted in exposure misclassification. In the United States, it is estimated
that one third of type II diabetics are undiagnosed (55). However, we have no reason to
believe that this misclassification would differ between cases and controls; thus any error
from this source is most likely to bias results toward the null. The heterogeneity of HNC
may also hinder the ability to adequately examine whether diabetes is a risk factor. Weak or
inconsistent associations with all HNC may result if the subtypes of HNC are etiologically
distinct. Although we performed analyses for separate sites (larynx, hypopharynx,
oropharynx, oral cavity, and non-specific pharynx), small sample sizes prevented
meaningful interpretation of the results. The inability to control for HPV infection is a
further limitation. However, cancers occurring in the oropharynx, as opposed to other HNC
sites, are most strongly associated with HPV infection (27,56,57), and we are not aware of
any studies that suggest that diabetics are more likely to be infected with HPV.
We did not have sufficient data to adjust for factors such as diabetic medication use or
extent of glycemic control in this study. Many diabetics are able to maintain good glycemic
control and/or lowered insulin levels by oral hypoglycemic agents, diet, appropriate use of
exogenous insulin, etc. In addition, recent evidence suggests that some oral hypoglycemic
agents used to treat diabetes, such as metformin, may reduce incidence of a wide variety of
cancers (58). Researchers have observed an association of use of exogenous insulin with
increased risk of cancer of the breast, colon, pancreas, prostate, or any solid tumor (59), and
increased risk of death from any type of cancer (60). Among 710 subjects who reported a
history of diabetes and who had data on insulin use in the present study, 33% were insulin
users. Between the years 1997 to 2008 in the United States, the proportion of diabetics aged
65–74 using any diabetes medication (pills, insulin or both) ranged from 83.2% to 90.0%
(61). Even if rates of medication use are not this high in our international pooled data, it is
nonetheless likely that a large percentage of diabetics were taking oral hypoglycemic agents.
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Thus, the diabetes effect in the absence of treatment might be stronger than the association
observed in our study.
Selection bias may have influenced results in a positive or negative direction. Diabetics are
more likely to have multiple hospitalizations than non-diabetics (62,63), creating a selection
bias when controls are recruited in hospital-based studies. The possible influence of bias due
to controls in hospital-based studies was difficult to evaluate because exclusion of the
hospital-based studies increased the proportional influence of the North Carolina study on
the results, attenuating the odds ratio toward the null. An alternative source of selection bias
may occur if control participants are systematically healthier than control non-participants,
thus spuriously raising the OR. However, this source of bias is unlikely because the pooled
OR for studies with control participation rates less than 90% was almost identical to the OR
for studies with control participation above 90%.
Conclusion
In this large pooled analysis of 12 case-control studies, we observed a weak association
between diabetes and HNC in all subjects, adjusting for several potential confounders;
however, we did find a modest association among never smokers. Prospective studies, with
data that more accurately captures potential confounding relationships, may provide insight
into a possible relationship between glucose metabolism abnormalities and HNC.
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Figure 1. Forest plot of study-specific ORs and 95% CIs for the association between history of
diabetes and HNC risk, INHANCE Pooled Case-Control Study of Head and Neck Cancer
The squares represent the OR estimates and the horizontal lines represent the 95% CIs for
each study. The area of the square reflects the weight that the study contributes. This
random-effects model incorporates an estimate of between-study heterogeneity in the
weighting. The diamond at the center indicates the random-effects estimate and the width of
the diamond indicates the 95% CI.
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Figure 2. Influence analyses of single studies on the overall estimate for the association between
history of diabetes and HNC risk, INHANCE Pooled Case-Control Study of Head and Neck
Cancer
The circle for each study represents the OR estimate and the horizontal line represents the
95% CI from the pooled data after excluding that study. The three vertical lines represent the
random-effects pooled point estimate and associated 95% CI.
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